nature portfolio

Corresponding author(s): Dr. Gábor Harami, Dr. Mihály Kovács

Last updated by author(s): Aug 16, 2021

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Statistics

For	all st	atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.	
n/a	Confirmed		
	\boxtimes	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement	
	\square	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly	
	\boxtimes	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.	
\boxtimes		A description of all covariates tested	
\boxtimes		A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons	
	\boxtimes	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)	
\boxtimes		For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.	
\boxtimes		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings	
\boxtimes		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes	
\boxtimes		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated	
		Our web collection on statistics for biologists contains articles on many of the points above.	

Software and code

Policy information	about <u>availability of computer code</u>
Data collection	Fluorescence anisotropy: inbuilt software for Synergy H4 Hybrid Multi-Mode Microplate Reader (BioTek); fluorescent image scanning: inbuilt softvare for Typhoon TRIO+ Variable Mode Imager (Amersham Biosciences)
Data analysis	Data representation and fitting: OriginLab 8.0 (Microcal corp.), Pixel densitometry: GelQuant Pro (DNR Bio Imaging Ltd.), Kinteic modeling: KinTek Global Kinetic Explorer 4.0 (KinTek). (corresponding references included in the manuscript)

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

All data generated or analysed during this study are included in this published article (and its supplementary information files).

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

🔀 Life sciences

Behavioural & social sciences

Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	We have not calculated sample sizes priori to experiments, instead we aimed to have at least 3 biological replications usually used in similar in vitro studies.
Data exclusions	No data were excluded from this study.
Replication	Sample sizes are reported for all measurements in Figure legends and in the Methods section.
Randomization	There was no experimental group allocations for this study. The activities of our protein variants were measured paralelly in a random order.
Blinding	Blinding was not relevant for our in vitro studies as there was no experimental group allocations and biophyiscal parameters were quantitatively assed along with the prorer controls. compared.

Reporting for specific materials, systems and methods

Matle a de

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
\boxtimes	Antibodies
\boxtimes	Eukaryotic cell lines
\boxtimes	Palaeontology and archaeology
\boxtimes	Animals and other organisms
\boxtimes	Human research participants
\boxtimes	Clinical data
\boxtimes	Dual use research of concern

Methous							
n/a	Involved in the study						
\boxtimes	ChIP-seq						
\boxtimes	Flow cytometry						

MRI-based neuroimaging